ABAnna M. Becker

Anna M. Becker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna M. Becker has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Matthias E. Liechti

    Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland

    9 shared publications
  • Friederike Holze

    Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland

    6 shared publications
  • Dino Luethi

    Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland

    4 shared publications
  • Lorenz Mueller

    Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland

    4 shared publications
  • Aaron Klaiber

    Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland

    3 shared publications
  • Laura Ley

    Psychopharmacology Research, Division of Clinical Pharmacology & Toxicology, Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland

    3 shared publications

Latest Publications

  • Open Access

    LSD treatment affects working memory-related brain function in patients with major depressive disorder

    by Friederike Holze, Kristian Larsen, Brice Ozenne, Gitte M. Knudsen, Anna M. Becker, Mihai Avram, Stefan Borgwardt, Matthias E. Liechti, Felix Müller, Patrick M. Fisher

    Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on working memory-related brain function in patients with MDD. In a randomized, double-blind, parallel-group trial, 43 patients with MDD received either two low-dose (25 µg) or two high-dose (100 and 200 µg) oral LSD treatments 4 weeks apart. Functional magnetic resonance imaging during an n-back working memory task was conducted before and approximately 1 week after the second treatment. The treatment × time interaction effect on working memory-related brain responses (2-back and 1-back vs . 0-back) was assessed using linear mixed effects models. We also explored associations between brain responses and depression severity, task performance, and subjective psychedelic experiences. Compared with low-dose treatment, high-dose LSD treatment significantly increased working memory-related brain responses ( p = 0.007) within task-activated regions, including the dorsolateral prefrontal cortex, parietal cortex, insula, striatum, and thalamus. Working memory-related brain responses correlated with task performance and subjective perceptual changes but not treatment response. Our observations provide the first evidence that LSD treatment in patients with MDD affects cognitive brain function. Contrary to our hypothesis, high-dose LSD significantly increased brain responses. These responses positively correlated with task performance, suggesting a potential LSD-induced boost in neural function. The absence of an association with depressive symptoms indicates that task-related brain activity may underlie different mechanisms than changes in mood. Trial registration: Clinicaltrials.gov Identifier: NCT03866252.

  • Open Access

    Psychedelics Restructure the Global Workspace of Consciousness

    by Parsa Yousefi, Kenneth Shinozuka, Patrick Vizeli, Friederike Holze, Anna M. Becker, Felix Müller, Matthias E. Liechti, Gregor Hasler, Carolyn I. Rodríguez, Andrea Luppi, et al.

    Psychoactive drugs profoundly alter consciousness, but the neural mechanisms by which they do so remain poorly understood. Global workspace theory may provide a framework for investigating these mechanisms. The global workspace, a candidate neural substrate of consciousness, is a set of brain regions that integrate and disseminate information to the rest of the brain. According to a recent model, the integrators, or “gateways,” are characterized by synergistic interactions with other brain regions, while the disseminators, or “broadcasters,” exhibit redundant interactions. Here, we measured the effects of various psychoactive drugs, including “classic” psychedelics like LSD, mescaline, and psilocybin, “atypical” psychedelics (entactogens) like MDMA, and the stimulant D-amphetamine, on the global workspace. In a secondary analysis of resting-state functional magnetic resonance imaging (fMRI) data on all these drugs, we found that classic psychedelics are associated with significant increases in the number of gateways in the frontoparietal control and dorsal attention networks. Meanwhile, MDMA and amphetamine reduced the number of gateways in the visual and somatomotor networks. The regional topographies of both synergy and redundancy distinguished classic psychedelics from other drugs. Finally, drugs producing similar changes in synergy and redundancy also produced similar profiles of subjective effects. Overall, our findings provide the first direct evidence that psychedelics may alter the synergistic and redundant interactions that characterize the global workspace of consciousness.

  • Open Access

    Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study

    by Mélusine Humbert-Droz, Anna M. Becker, Jan Valenta, Deborah Rudin, Dino Luethi, Ina Vukalovic, Anne Eckert, Matthias E. Liechti, Lorenz Mueller

    3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is being investigated as a treatment for several psychiatric disorders, particularly posttraumatic stress disorder. Phase 2 and 3 trials typically administered a first dose of MDMA followed by a second “booster” dose 1.5–2.5 h later, to extend the acute effect duration. However, the risks and benefits of the booster dose have not been systematically investigated. In this double-blind, randomized, placebo-controlled, cross-over study, we compared 120 mg MDMA followed by a 60 mg booster dose or placebo after 2 h, and placebo followed by placebo. The primary outcome was the overall duration of any subjective drug effects, measured by a Visual Analog Scale. Secondary outcomes included additional subjective effects, adverse effects, vital signs, and plasma concentrations of MDMA, oxytocin, and neurophysin I. Twenty-five healthy volunteers were included, and twenty-three (12 male, 11 female) completed all dosing sessions. The booster dose of MDMA prolonged the acute subjective effects of MDMA compared with the single dose (mean ± SD, 5.6 ± 1.8 h vs . 4.6 ± 1.2 h, p = 0.001), while no differences in subjective or autonomic peak effects were observed. Acute (0–9 h) and subacute (up to 3 days) adverse effects were more common after both MDMA conditions than placebo. These results indicate that acute MDMA effects can be prolonged by using a booster dose, as intended in clinical trials of MDMA-AT. Whether this translates into clinical benefit remains to be investigated.


  • Open Access

    Psychedelics distinctly alter brain entropy and complexity compared to psychostimulants

    by Kristian Larsen, Patrick M Fisher, Drummond E. McCulloch, Anders S. Olsen, Felix Mueller, Matthias Liechti, Stefan Borgwardt, Friederike Holze, Patrick Vizeli, Laura Ley, et al.

    Classical psychedelics have regained interest for their potential to treat psychiatric and neurological disorders, and explore neural mechanisms supporting perception, cognition, and mood. Acute psychedelic effects have been linked to increases in brain complexity and entropy, but it is unclear if these changes are specific to psychedelics or reflect more general psychoactive effects. Here, we examined whether brain complexity and entropy metrics can identify features specific to the psychedelic state. Using resting-state fMRI from three placebo-controlled crossover trials (N=79; 255 sessions), we compared LSD, psilocybin, and mescaline with psychostimulants MDMA and d-Amphetamine. Compared to stimulants, psychedelics produced significant increases in meta-state complexity, short-timescale multiscale entropy, and dynamic conditional correlation entropy. Both drug classes increased Lempel-Ziv and spatial complexity, and decreased absolute modularity. Our findings highlight psychedelic-specific effects on brain signals that distinguish the acute psychedelic state from other psychoactive drug effects and may be relevant for understanding their therapeutic potential.


  • Open Access

    The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research

    by Kurt Stocker, Matthias Hartmann, Yasmin Schmid, Severin B. Vogt, Anna M. Becker, Laura Ley, Isabelle Straumann, Denis Arikci, Aaron Klaiber, Livio Erne, et al.

    Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC remains widely used for summarizing broader experiential domains. Aims: We wanted to provide an updated, psychometrically revalidated version of the ASC. We tested whether the 42-item 11-ASC could be integrated into a coherent three-dimensional framework. We further hypothesized that this revised model would outperform the original 66-item 3D-ASC while preserving its conceptual clarity. Methods: Data from 901 5D-ASC questionnaires from 398 healthy participants across 16 randomized, mostly placebo-controlled psychedelic (lysergic acid diethylamide, psilocybin, mescaline, and N , N -dimethyltryptamine) studies were split for exploratory and confirmatory factor analysis. We compared the 3D-ASC and 11-ASC in terms of reliability and model fit, and tested whether the 11-ASC could be summarized within a three-dimensional model. Results: Ten of the 11 subscales formed three higher-order dimensions—Positive (PosE), Distressing (DisE), and Perceptual (PerE) effects—mirroring the 3D-ASC but with improved fit. We propose this as the 3D-ASCr scale. The Anxiety subscale could not be integrated due to consistent floor effects (low anxiety in the sample), but given its clinical relevance, it is retained within 3D-ASCr (as part of DisE or a standalone subscale). Conclusion: The 3D-ASCr is an updated version of the ASC and is recommended for use with classic serotonergic psychedelics in both clinical practice and research.


  • Open Access

    Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants

    by Lorenz Mueller, Aaron Klaiber, Laura Ley, Anna M. Becker, Jan Thomann, Dino Luethi, Yasmin Schmid, Matthias E. Liechti

    Background and Objective Mescaline is a classic serotonergic psychedelic with a long history of human use. The present study analyzed the pharmacokinetics, pharmacokinetic-pharmacodynamic relationship, and urinary recovery of oral mescaline hydrochloride. Methods Data from 105 single-dose administrations (100–800 mg) in 49 participants from two phase I trials were analyzed with compartmental pharmacokinetics and pharmacokinetic-pharmacodynamic modeling. A one-compartment model with first-order absorption, elimination, and a lag time was used to describe mescaline plasma concentrations. Acute subjective effects, assessed by visual analog scales (range 0–100%), were modeled using a sigmoid Emax model linked to plasma concentrations via a first-order rate constant (ke0). Results Mescaline showed dose-proportional increases in total exposure and maximal concentrations, with a peak concentration reached within 2.0 h (geometric mean) and a half-life of 3.5 h across all doses. Mean model-predicted onset of “any drug effect” occurred around 1 hour post-dose. Maximum predicted effect intensity and duration increased with dose, from 13% and 2.8 h at 100 mg to 89% and 15 h at 800 mg. Over all conditions, 53% of the dose was excreted into urine unchanged, and 31% was excreted as the main metabolite 3,4,5-trimethoxyphenylacetic acid over 24–30 h. Conclusions These findings provide the first detailed pharmacokinetic-pharmacodynamic characterization of mescaline in humans and indicate an oral bioavailability of at least 53%, limited by first-pass metabolism to 3,4,5-trimethoxyphenylacetic acid, followed by predominant renal elimination of both analytes. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04227756 and NCT04849013.


  • Open Access

    Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

    by Anna M. Becker, Mélusine Humbert‐Droz, Lorenz Mueller, Alen Jelušić, Avram Tolev, Isabelle Straumann, Isidora Avedisian, Livio Erne, Jan Thomann, Dino Luethi, et al.

    Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants. Paroxetine did not alter pleasant subjective effects of LSD but significantly reduced “bad drug effect,” “anxiety,” and “nausea.” No differences in autonomic effects or QTc interval after LSD administration were found between both conditions. The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism. The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers. The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated. The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6. For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.


  • Open Access

    Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

    by Livio Erne, Severin B. Vogt, Lorenz Müller, Albiona Nuraj, Anna Becker, Aaron Klaiber, Melani Zuparic, Nimmy Varghese, Anne Eckert, Deborah Rudin, et al.

    N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that is known for its short-lasting effects when administered intravenously. Several studies have investigated the administration of intravenous boluses or combinations of a bolus and a subsequent continuous infusion. However, data on dose-dependent acute effects and pharmacokinetics of continuous DMT infusions are lacking. We used a double-blind, randomized, placebo-controlled, crossover design in 22 healthy participants (11 women, 11 men) who received placebo and DMT (0.6, 1.2, 1.8, and 2.4 mg/min) over an infusion duration of 120 min. We also tested a self-guided titration scheme that allowed participants to adjust the DMT dose rate at prespecified time points to achieve their desired level of subjective effects. Outcome measures included subjective effects, autonomic effects, adverse effects, plasma hormone concentrations, and pharmacokinetics up to 3 h after starting the infusion. DMT infusions exhibited dose-proportional pharmacokinetics and rapidly induced dose-dependent subjective effects that reached a plateau after 30 min. A ceiling effect was observed for “good drug effect” at 1.8 mg/min. The 2.4 mg/min dose of DMT induced greater anxious ego dissolution than the 1.8 mg/min dose and induced significant anxiety compared with placebo. We observed moderate acute tolerance to acute effects of DMT. In the self-guided titration session, the participants opted for moderate to strong psychedelic effects, comparable in intensity to the 1.8 mg/min DMT dose rate in the randomized dosing sessions. These results may assist with dose finding for future DMT research and demonstrate that acute subjective effects of DMT can be rapidly adjusted through dose titration.


  • Open Access

    Safety pharmacology of acute psilocybin administration in healthy participants

    by Isabelle Straumann, Friederike Holze, Anna M. Becker, Laura Ley, Nepomuk Halter, Matthias E. Liechti


  • Top Cited Papers
    Open Access

    Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants

    by Friederike Holze, Anna M. Becker, Karolina E. Kolaczynska, Urs Duthaler, Matthias E. Liechti

    Psilocybin is being investigated as a potential treatment for psychiatric and neurological disorders. Only a few studies have evaluated the pharmacokinetics (PKs) of psilocybin and have used body weight‐adjusted dosing. Data on PKs and the PK‐pharmacodynamic (PD) relationship of fixed doses that are commonly used are unavailable. The present study characterized the PKs and PK‐PD relationship of 15, 25, and 30 mg of orally administered psilocybin in 28, 23, and 28 healthy subjects, respectively. Plasma levels of unconjugated psilocin (the psychoactive metabolite of psilocybin) and corresponding subjective effects were repeatedly assessed up to 24 hours. PK parameters were determined using compartmental modeling. Concentration‐subjective effect relationships were described using PK‐PD modeling. Mean (95% confidence interval) maximal psilocin concentrations were 11 ng/mL (10‐13), 17 ng/mL (16‐19), and 21 ng/mL (19‐24) after the administration of 15, 25, and 30 mg psilocybin, respectively. Maximal concentrations were reached after an average of 2 hours. Elimination half‐lives were 1.8 hours (1.7–2.0), 1.4 hours (1.2–1.7), and 1.8 hours (1.6–1.9) for 15, 25, and 30 mg psilocybin, respectively. Mean (± SD) durations of subjective effects were 5.6 ± 2.2 hours, 5.5 ± 1.6 hours, and 6.4 ± 2.2 hours, and maximal effects (“any drug” effects) were 58% ± 25%, 73% ± 27%, and 80% ± 18% after 15, 25, and 30 mg psilocybin, respectively. Psilocin exhibited dose‐proportional PKs. The duration and intensity of subjective effects were dose‐dependent. Body weight did not influence pharmacokinetics or the response to psilocybin. These data may serve as a reference for future clinical trials.